Gilead Sciences Shares Outstanding 2010-2022 | GILD

Gilead Sciences shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Gilead Sciences shares outstanding for the quarter ending September 30, 2022 were 1.261B, a 0.08% decline year-over-year.
  • Gilead Sciences 2021 shares outstanding were 1.262B, a 0.08% decline from 2020.
  • Gilead Sciences 2020 shares outstanding were 1.263B, a 1.1% decline from 2019.
  • Gilead Sciences 2019 shares outstanding were 1.277B, a 2.37% decline from 2018.
Gilead Sciences Annual Shares Outstanding
(Millions of Shares)
2021 1,262
2020 1,263
2019 1,277
2018 1,308
2017 1,319
2016 1,358
2015 1,521
2014 1,647
2013 1,695
2012 1,583
2011 1,580
2010 1,747
2009 1,868
Gilead Sciences Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 1,261
2022-06-30 1,260
2022-03-31 1,262
2021-12-31 1,262
2021-09-30 1,262
2021-06-30 1,260
2021-03-31 1,262
2020-12-31 1,263
2020-09-30 1,261
2020-06-30 1,255
2020-03-31 1,270
2019-12-31 1,277
2019-09-30 1,267
2019-06-30 1,277
2019-03-31 1,283
2018-12-31 1,308
2018-09-30 1,307
2018-06-30 1,308
2018-03-31 1,320
2017-12-31 1,319
2017-09-30 1,319
2017-06-30 1,317
2017-03-31 1,320
2016-12-31 1,358
2016-09-30 1,339
2016-06-30 1,355
2016-03-31 1,412
2015-12-31 1,521
2015-09-30 1,503
2015-06-30 1,540
2015-03-31 1,569
2014-12-31 1,647
2014-09-30 1,637
2014-06-30 1,664
2014-03-31 1,680
2013-12-31 1,695
2013-09-30 1,692
2013-06-30 1,695
2013-03-31 1,665
2012-12-31 1,583
2012-09-30 1,585
2012-06-30 1,561
2012-03-31 1,555
2011-12-31 1,580
2011-09-30 1,563
2011-06-30 1,602
2011-03-31 1,624
2010-12-31 1,747
2010-09-30 1,694
2010-06-30 1,798
2010-03-31 1,857
2009-12-31 1,868
2009-09-30 1,865
2009-06-30 1,869
2009-03-31 1,885
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $104.541B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00